Roble Belko & Company’s Vanguard Health Care ETF VHT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$369K Buy
1,355
+1,195
+747% +$342K 0.05% 94
2025
Q4
$46K Buy
160
+5
+3% +$1.4K 0.01% 217
2025
Q3
$40K Hold
155
0.01% 185
2025
Q2
$38K Hold
155
0.01% 192
2025
Q1
$41K Hold
155
0.01% 181
2024
Q4
$39K Hold
155
0.01% 181
2024
Q3
$44K Hold
155
0.01% 171
2024
Q2
$41K Hold
155
0.01% 174
2024
Q1
$42K Hold
155
0.01% 182
2023
Q4
$39K Hold
155
0.01% 173
2023
Q3
$36K Hold
155
0.01% 157
2023
Q2
$38K Hold
155
0.01% 153
2023
Q1
$37K Hold
155
0.01% 163
2022
Q4
$38K Hold
155
0.01% 169
2022
Q3
$35K Hold
155
0.01% 168
2022
Q2
$37K Hold
155
0.01% 169
2022
Q1
$39K Hold
155
0.01% 176
2021
Q4
$41K Hold
155
0.01% 168
2021
Q3
$38K Hold
155
0.01% 159
2021
Q2
$38K Hold
155
0.01% 172
2021
Q1
$35K Hold
155
0.01% 167
2020
Q4
$35K Hold
155
0.01% 156
2020
Q3
$32K Hold
155
0.01% 157
2020
Q2
$30K Hold
155
0.01% 168
2020
Q1
$26K Buy
+155
New +$28.3K 0.01% 173

Other funds holding VHT

Roble Belko & Company's VHT Position: Q1 2026 in Review

Roble Belko & Company increased its Vanguard Health Care ETF (VHT) stake by 747% in Q1 2026, buying an estimated $342K and bringing the position to 1,355 shares worth $369K. The position accounts for 0.05% of the portfolio, ranked #94.

Roble Belko & Company first reported a position in VHT in Q1 2020 and has held it in 25 quarters since. 1,085 funds tracked by Wall St. Rank hold VHT as of Q1 2026.

  • Roble Belko & Company held 1,355 shares of Vanguard Health Care ETF worth $369K as of Q1 2026.
  • Roble Belko & Company bought 1,195 Vanguard Health Care ETF shares in Q1 2026, an estimated $342K.
  • Vanguard Health Care ETF made up 0.05% of Roble Belko & Company's portfolio in Q1 2026, its #94 holding.
  • Roble Belko & Company first reported a position in Vanguard Health Care ETF in Q1 2020 and has held it in 25 quarters since.
  • 1,085 funds tracked by Wall St. Rank held Vanguard Health Care ETF as of Q1 2026.

Based on Roble Belko & Company's 13F filing for Q1 2026, filed 16 Apr 2026.